The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06551324




Registration number
NCT06551324
Ethics application status
Date submitted
25/07/2024
Date registered
13/08/2024
Date last updated
14/07/2025

Titles & IDs
Public title
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Scientific title
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
Secondary ID [1] 0 0
2024-511650-50-00
Secondary ID [2] 0 0
C2321014
Universal Trial Number (UTN)
Trial acronym
MEVPRO-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Castrate Resistant Prostate Cancer (mCRPC) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PF-06821497
Treatment: Drugs - Docetaxel
Treatment: Drugs - Enzalutamide

Experimental: Arm A - Investigational Arm A: PF-06821497 875 mg twice daily (BID) + enzalutamide 160 mg every day (QD)

Active comparator: Arm B - Comparator Arm B: Physician's choice of enzalutamide 160 mg QD or docetaxel 75 mg/m2 intravenous (IV) every 21 days


Treatment: Drugs: PF-06821497
875 mg BID (2 times a day)

Treatment: Drugs: Docetaxel
75 mg/m2 IV (every 21 days)

Treatment: Drugs: Enzalutamide
160 mg QD

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)
Assessment method [1] 0 0
rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or in bone per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines by BICR, or death, whichever occurs first.
Timepoint [1] 0 0
Randomization up to approximately 2 years.
Secondary outcome [1] 0 0
Overall survival (OS)
Assessment method [1] 0 0
OS is defined as the time from the date of randomization to the date of death due to any cause.
Timepoint [1] 0 0
Randomization up to approximately 4.5 years.
Secondary outcome [2] 0 0
Objective Response (ORR)
Assessment method [2] 0 0
The objective response rate is defined as the proportion of participants with measurable soft tissue disease at baseline who have a confirmed objective response of complete response (CR) or partial response (PR) per RECIST v1.1.
Timepoint [2] 0 0
Randomization up to approximately 2 years.
Secondary outcome [3] 0 0
Duration of Response (DoR) in measurable soft tissue disease
Assessment method [3] 0 0
The DoR is defined as the first objective evidence of soft tissue response (CR or PR, whichever is earlier) to radiographic progression or death due to any cause whichever occurs first.
Timepoint [3] 0 0
Randomization up to approximately 2 years.
Secondary outcome [4] 0 0
Time to prostate specific antigen (PSA) progression.
Assessment method [4] 0 0
Proportion of participants with PSA response =50% in participants with detectable PSA values at baseline.
Timepoint [4] 0 0
Randomization up to approximately 2 years.
Secondary outcome [5] 0 0
Time to initiation of antineoplastic therapy.
Assessment method [5] 0 0
Time from randomization to first use of new antineoplastic therapy.
Timepoint [5] 0 0
Randomization up to approximately 4.5 years.
Secondary outcome [6] 0 0
Prostate Specific Antigen Response
Assessment method [6] 0 0
Proportion of participants with PSA response =50% in participants with detectable PSA values at baseline.
Timepoint [6] 0 0
Randomization up to approximately 2 years.
Secondary outcome [7] 0 0
Incidence of Adverse Events
Assessment method [7] 0 0
Type, incidence, severity \[as graded by National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v5.0\], seriousness and relationship to study medications of AEs.
Timepoint [7] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [8] 0 0
Time to first symptomatic skeletal event
Assessment method [8] 0 0
Time from randomization to first symptomatic skeletal event (symptomatic bone fractures, spinal cord compression, surgery or radiation to the bone whichever is first).
Timepoint [8] 0 0
Randomization up to approximately 2 years.
Secondary outcome [9] 0 0
Change from baseline in patient reported pain symptoms per Brief Pain Inventory-Short Form (BPI-SF)
Assessment method [9] 0 0
Analysis of Brief Pain Inventory-Short Form (BPI-SF) will be based on the pain severity score (mean of individual BPI-SF items 3, 4, 5 and 6), the pain interference score (mean of items 9A-9G), and the single BPI-SF Item 3 which asks the patient to rate pain at its worst in the last 24 hours.
Timepoint [9] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [10] 0 0
Change from baseline in health-related quality of life (HRQoL) per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
Assessment method [10] 0 0
Change from baseline in HRQoL (FACT-P total score) will be presented. The FACT-P total score will be calculated based on the participant responses to the 39 items in the FACT-P questionnaire. Each item is rated on a 0 to 4 Likert-type scale and then combined to produce the FACT-P total score (0-156), with higher scores representing better health-related quality of life.
Timepoint [10] 0 0
Randomization to approximately 4.5 years
Secondary outcome [11] 0 0
Change from baseline in social/family well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
Assessment method [11] 0 0
Change from baseline in social/family well-being score will be presented. The social/family well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale
Timepoint [11] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [12] 0 0
Change from baseline in emotional well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
Assessment method [12] 0 0
Change from baseline in emotional well-being score will be presented. The emotional well-being score will be calculated based on 6 items in the FACT-P questionnaire; score range 0-24. Each item is rated on a 0 to 4 Likert-type scale
Timepoint [12] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [13] 0 0
Change from baseline in functioning well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
Assessment method [13] 0 0
Change from baseline in functioning well-being score will be presented. The functioning well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale
Timepoint [13] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [14] 0 0
Change from baseline in physical well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
Assessment method [14] 0 0
Change from baseline in physical well-being score will be presented. The physical well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale
Timepoint [14] 0 0
Randomization to approximately 4.5 years
Secondary outcome [15] 0 0
Change from baseline in symptoms per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
Assessment method [15] 0 0
Change from baseline prostate cancer symptoms (PCS) score will be presented. The PCS score will be calculated based on 12 items in the FACT-P questionnaire; score range 0-48. Each item is rated on a 0 to 4 Likert-type scale
Timepoint [15] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [16] 0 0
Change from baseline in patient reported health status per European Quality of Life 5-Dimension 5 Level (EQ-5D-5L)
Assessment method [16] 0 0
Participants will self-rate their current state of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression by choosing 1 of 5 possible responses that record the level of severity (no problems, slight problems, moderate problems, severe problems, or extreme problems) within each dimension. The questionnaire also includes a visual analog scale to self-rate general health state on a scale from "the worst health you can imagine" to "the best health you can imagine."
Timepoint [16] 0 0
Randomizaton up to approximately 4.5 years
Secondary outcome [17] 0 0
Symptomatic toxicity as measured by items from the Patient-Reported Outcome CTCAE (PRO-CTCAE)
Assessment method [17] 0 0
Each selected PRO-CTCAE items will be assessed related to one or more attributes that include counts for the frequency, severity, and/or interference with usual or daily activities.
Timepoint [17] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [18] 0 0
Overall side effect burden as measured by the FACT- GP5
Assessment method [18] 0 0
The FACT-GP5 question assesses overall side effect burden with the following response options "I am bothered by side effects of treatment," is rated on a 5-point scale ranging from "not at all" (0) to "very much" (4) and counts will be presented.
Timepoint [18] 0 0
Randomization to approximately 4.5 years
Secondary outcome [19] 0 0
Time to confirmatory deterioration in patient-reported pain symptoms per BPI-SF Item 3 "worst pain in 24 hours"
Assessment method [19] 0 0
Defined as the time from randomization to onset of pain progression, which is defined as \> 2-point increase from baseline in the score from the BPI-SF Question 3 that is confirmed at the next consecutive assessment \> 4 weeks apart or an initial deterioration followed by death before the next assessment
Timepoint [19] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [20] 0 0
Time to definitive deterioration in patient-reported health related quality of life (HRQoL) per FACT-P
Assessment method [20] 0 0
Defined as the time from randomization to onset of definitive deterioration in FACT-P total score, which is defined as \>10 point decrease from baseline and no subsequent observations with a \<10 point decrease from baseline FACT-P total score
Timepoint [20] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [21] 0 0
Time to definitive deterioration in patient-reported physical well-being per FACT-P
Assessment method [21] 0 0
Time to definitive deterioration in physical well-being (PWB) per FACT-P is defined as the time from randomization to onset of definitive deterioration in physical well-being, which is defined as =3-point
Timepoint [21] 0 0
Randomization up to approximately 4.5 years
Secondary outcome [22] 0 0
To evaluate the PK of PF-06821497 when dosed with enzalutamide
Assessment method [22] 0 0
PK characterized by pre-dose trough and post-dose plasma concentrations of PF-06821497 at selected visits.
Timepoint [22] 0 0
Cycle 1 (each cycle is 28 days), Day 1 to last PK draw at the end of Cycle 6, Day 1.
Secondary outcome [23] 0 0
To assess circulating tumor DNA (ctDNA) at baseline and on treatment to evaluate tumor burden.
Assessment method [23] 0 0
Evaluation of ctDNA burden at baseline and on study.
Timepoint [23] 0 0
Baseline up to approximately 2 years.

Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
* Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
* Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required.
* Eastern Cooperate Oncology Group (ECOG) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator.
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study.
* Know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
* Clinically significant cardiovascular disease.
* Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure.
* Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177Lu-PSMA-617, radium 223), androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment, with the following exceptions:

1. Treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention.
2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion.
* Previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is shorter).
* Inadequate organ function.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Icon Cancer Centre Wesley - Auchenflower
Recruitment hospital [2] 0 0
Monash Health - Clayton
Recruitment hospital [3] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
4066 - Auchenflower
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Maine
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Córdoba
Country [21] 0 0
Brazil
State/province [21] 0 0
Ceará
Country [22] 0 0
Brazil
State/province [22] 0 0
RIO Grande DO SUL
Country [23] 0 0
Brazil
State/province [23] 0 0
SÃO Paulo
Country [24] 0 0
Brazil
State/province [24] 0 0
São Paulo
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
China
State/province [28] 0 0
Anhui
Country [29] 0 0
China
State/province [29] 0 0
Beijing
Country [30] 0 0
China
State/province [30] 0 0
Chongqing
Country [31] 0 0
China
State/province [31] 0 0
Fujian
Country [32] 0 0
China
State/province [32] 0 0
Gansu
Country [33] 0 0
China
State/province [33] 0 0
Guangdong
Country [34] 0 0
China
State/province [34] 0 0
Guangxi
Country [35] 0 0
China
State/province [35] 0 0
Hubei
Country [36] 0 0
China
State/province [36] 0 0
Hunan
Country [37] 0 0
China
State/province [37] 0 0
Jiangsu
Country [38] 0 0
China
State/province [38] 0 0
Liaoning
Country [39] 0 0
China
State/province [39] 0 0
Shaanxi
Country [40] 0 0
China
State/province [40] 0 0
Shandong
Country [41] 0 0
China
State/province [41] 0 0
Shanghai
Country [42] 0 0
China
State/province [42] 0 0
Sichuan
Country [43] 0 0
China
State/province [43] 0 0
Zhejiang
Country [44] 0 0
Czechia
State/province [44] 0 0
Olomoucký KRAJ
Country [45] 0 0
Czechia
State/province [45] 0 0
Pardubický KRAJ
Country [46] 0 0
Czechia
State/province [46] 0 0
Praha 10
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 4
Country [48] 0 0
Czechia
State/province [48] 0 0
Hradec Králové
Country [49] 0 0
Czechia
State/province [49] 0 0
Pardubice
Country [50] 0 0
France
State/province [50] 0 0
Alpes-maritimes
Country [51] 0 0
France
State/province [51] 0 0
Alsace
Country [52] 0 0
France
State/province [52] 0 0
Finistère
Country [53] 0 0
France
State/province [53] 0 0
Gard
Country [54] 0 0
France
State/province [54] 0 0
Haute-garonne
Country [55] 0 0
France
State/province [55] 0 0
Hauts-de-seine
Country [56] 0 0
France
State/province [56] 0 0
Ille-et-vilaine
Country [57] 0 0
France
State/province [57] 0 0
Marne
Country [58] 0 0
France
State/province [58] 0 0
Rhône-alpes
Country [59] 0 0
France
State/province [59] 0 0
Rhône
Country [60] 0 0
France
State/province [60] 0 0
Val-de-marne
Country [61] 0 0
France
State/province [61] 0 0
Clermont-Ferrand
Country [62] 0 0
Germany
State/province [62] 0 0
Baden-württemberg
Country [63] 0 0
Germany
State/province [63] 0 0
Nordrhein-westfalen
Country [64] 0 0
Germany
State/province [64] 0 0
Hamburg
Country [65] 0 0
Greece
State/province [65] 0 0
Attikí
Country [66] 0 0
Hungary
State/province [66] 0 0
Gyor-moson-sopron
Country [67] 0 0
Hungary
State/province [67] 0 0
Pest
Country [68] 0 0
Italy
State/province [68] 0 0
Emilia-romagna
Country [69] 0 0
Italy
State/province [69] 0 0
Lazio
Country [70] 0 0
Italy
State/province [70] 0 0
Milano
Country [71] 0 0
Japan
State/province [71] 0 0
Chiba
Country [72] 0 0
Japan
State/province [72] 0 0
Ehime
Country [73] 0 0
Japan
State/province [73] 0 0
Hokkaido
Country [74] 0 0
Japan
State/province [74] 0 0
Hyogo
Country [75] 0 0
Japan
State/province [75] 0 0
Ishikawa
Country [76] 0 0
Japan
State/province [76] 0 0
Kanagawa
Country [77] 0 0
Japan
State/province [77] 0 0
Osaka
Country [78] 0 0
Japan
State/province [78] 0 0
Tokyo
Country [79] 0 0
Japan
State/province [79] 0 0
Fukuoka
Country [80] 0 0
Japan
State/province [80] 0 0
Kumamoto
Country [81] 0 0
Japan
State/province [81] 0 0
Yamagata
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Jeonranamdo
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Kyonggi-do
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Seoul-teukbyeolsi [seoul]
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Taegu-kwangyokshi
Country [86] 0 0
Netherlands
State/province [86] 0 0
Fryslân
Country [87] 0 0
Netherlands
State/province [87] 0 0
Gelderland
Country [88] 0 0
Netherlands
State/province [88] 0 0
Noord-holland
Country [89] 0 0
Netherlands
State/province [89] 0 0
Utrecht
Country [90] 0 0
Poland
State/province [90] 0 0
Dolnoslaskie
Country [91] 0 0
Poland
State/province [91] 0 0
Kujawsko-pomorskie
Country [92] 0 0
Poland
State/province [92] 0 0
Malopolskie
Country [93] 0 0
Poland
State/province [93] 0 0
Zachodniopomorskie
Country [94] 0 0
Slovakia
State/province [94] 0 0
Bratislava
Country [95] 0 0
Slovakia
State/province [95] 0 0
Kosice
Country [96] 0 0
Slovakia
State/province [96] 0 0
Martin
Country [97] 0 0
Slovakia
State/province [97] 0 0
Presov
Country [98] 0 0
Slovakia
State/province [98] 0 0
Trnava
Country [99] 0 0
South Africa
State/province [99] 0 0
Eastern CAPE
Country [100] 0 0
South Africa
State/province [100] 0 0
Gauteng
Country [101] 0 0
South Africa
State/province [101] 0 0
Western CAPE
Country [102] 0 0
Spain
State/province [102] 0 0
Catalunya [cataluña]
Country [103] 0 0
Spain
State/province [103] 0 0
Madrid, Comunidad DE
Country [104] 0 0
Spain
State/province [104] 0 0
Madrid
Country [105] 0 0
Spain
State/province [105] 0 0
Manresa
Country [106] 0 0
Spain
State/province [106] 0 0
València
Country [107] 0 0
Sweden
State/province [107] 0 0
Stockholms LÄN [se-01]
Country [108] 0 0
Sweden
State/province [108] 0 0
Västra Götalands LÄN [se-14]
Country [109] 0 0
Taiwan
State/province [109] 0 0
Kaohsiung
Country [110] 0 0
Taiwan
State/province [110] 0 0
Taichung
Country [111] 0 0
Taiwan
State/province [111] 0 0
Tainan
Country [112] 0 0
Taiwan
State/province [112] 0 0
Taipei
Country [113] 0 0
Taiwan
State/province [113] 0 0
Taoyuan
Country [114] 0 0
Turkey
State/province [114] 0 0
I?stanbul
Country [115] 0 0
Turkey
State/province [115] 0 0
Ankara
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Blackburn WITH Darwen
Country [117] 0 0
United Kingdom
State/province [117] 0 0
London, CITY OF
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Midlothian
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Glasgow
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Country 0 0
Phone 0 0
1-800-718-1021
Email 0 0
ClinicalTrials.gov_Inquiries@pfizer.com
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.